Afghanistan vs Marshall Islands: Share of one-year-olds vaccinated against rotavirus
Afghanistan
56.0%
in 2024
Marshall Islands
44.0%
in 2024
Afghanistan rank
99th
Marshall Islands rank
102nd
Share of one-year-olds vaccinated against rotavirus over time
- Afghanistan
- Marshall Islands
How they compare
Afghanistan currently reports 56.0% against 44.0% in Marshall Islands, a difference of 12.0%.
That makes Afghanistan's figure about 1.3 times Marshall Islands's.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Afghanistan ahead.
Afghanistan ranks 99th and Marshall Islands ranks 102nd of 108 countries.
Across the 2 decades both report, Afghanistan averaged higher in 1 and Marshall Islands in 1.
Head to head by decade
| Decade | Afghanistan | Marshall Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 47.5% | 51.0% | 3.5% | Marshall Islands |
| 2020s | 53.4% | 49.4% | 4.0% | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of one-year-olds vaccinated against rotavirus, Afghanistan or Marshall Islands?
- Afghanistan, at 56.0% against 44.0% in Marshall Islands as of 2024.
- What is the difference in share of one-year-olds vaccinated against rotavirus between Afghanistan and Marshall Islands?
- 12.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Marshall Islands?
- 7 years are reported by both, from 2018 to 2024.
- How do Afghanistan and Marshall Islands rank globally for share of one-year-olds vaccinated against rotavirus?
- Afghanistan ranks 99th and Marshall Islands ranks 102nd of 108 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Share of one-year-olds vaccinated against rotavirus. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the final recommended dose (2nd or 3rd) of the rotavirus vaccine in a given year.